Do analysts recommend TPST or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to TPST or ONCO?

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 1 articles in the media. Tempest Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INAB or ONCO?

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 187.77%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, INAB or ONCO?

Onconetix has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Onconetix $810K 3.57 -$14.03M $248.12 0.00

Is INAB or ONCO more profitable?

IN8bio has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. IN8bio's return on equity of -91.18% beat Onconetix's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Onconetix -1,575.89% -91.95% -53.76%

Does the media refer more to INAB or ONCO?

In the previous week, IN8bio had 1 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for Onconetix. IN8bio's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ONCO or LSTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor ONCO or LSTA?

In the previous week, Lisata Therapeutics had 2 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Onconetix. Lisata Therapeutics' average media sentiment score of 0.33 beat Onconetix's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ONCO or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Onconetix (ONCO) Competitors

$0.66 0.00 (-0.32%)

As of 11:07 AM Eastern

Compare

ONCO vs. VTGN, TPST, INAB, LSTA, and ANEB

Should you buy Onconetix stock or one of its competitors? Onconetix's main competitors and comparable companies include VistaGen Therapeutics (VTGN), Tempest Therapeutics (TPST), IN8bio (INAB), Lisata Therapeutics (LSTA), and Anebulo Pharmaceuticals (ANEB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Onconetix compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

VistaGen Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.61, meaning that its share price is 161% more volatile than the broader market.

VistaGen Therapeutics presently has a consensus price target of $0.95, suggesting a potential upside of 279.09%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Onconetix has a net margin of -1,575.89% compared to VistaGen Therapeutics' net margin of -2,702.64%. Onconetix's return on equity of -91.95% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-2,702.64%	-152.59%	-117.45%
Onconetix	-1,575.89%	-91.95%	-53.76%

Onconetix has lower revenue, but higher earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	8.76	-$69.68M	-$1.66	N/A
Onconetix	$810K	3.57	-$14.03M	$248.12	0.00

In the previous week, Onconetix had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
Onconetix	Neutral

Summary

Onconetix beats VistaGen Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Onconetix compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Tempest Therapeutics has a beta of -1.73, suggesting that its stock price is 273% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.61, suggesting that its stock price is 161% more volatile than the broader market.

Tempest Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Onconetix	-1,575.89%	-91.95%	-53.76%

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 1 articles in the media. Tempest Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Onconetix has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Onconetix	$810K	3.57	-$14.03M	$248.12	0.00

Summary

Onconetix beats Tempest Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Onconetix compare to IN8bio?

IN8bio (NASDAQ:INAB) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Onconetix has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Onconetix	$810K	3.57	-$14.03M	$248.12	0.00

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 187.77%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, IN8bio had 1 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for IN8bio and 1 mentions for Onconetix. IN8bio's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IN8bio has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. IN8bio's return on equity of -91.18% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Onconetix	-1,575.89%	-91.95%	-53.76%

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

IN8bio has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.61, meaning that its stock price is 161% more volatile than the broader market.

Summary

IN8bio beats Onconetix on 8 of the 14 factors compared between the two stocks.

How does Onconetix compare to Lisata Therapeutics?

Onconetix (NASDAQ:ONCO) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Onconetix has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.57	-$14.03M	$248.12	0.00
Lisata Therapeutics	$100K	109.03	-$16.59M	-$1.64	N/A

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Onconetix has a beta of 2.61, meaning that its share price is 161% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, Lisata Therapeutics had 2 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Lisata Therapeutics and 1 mentions for Onconetix. Lisata Therapeutics' average media sentiment score of 0.33 beat Onconetix's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lisata Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Summary

Onconetix beats Lisata Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Onconetix compare to Anebulo Pharmaceuticals?

Onconetix (NASDAQ:ONCO) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.9% of Onconetix shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Onconetix. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.57	-$14.03M	$248.12	0.00
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Onconetix has a beta of 2.61, indicating that its share price is 161% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, indicating that its share price is 288% less volatile than the broader market.

In the previous week, Onconetix had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for Anebulo Pharmaceuticals. Onconetix's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Onconetix	Neutral
Anebulo Pharmaceuticals	Neutral

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Anebulo Pharmaceuticals' return on equity of -74.57% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Summary

Onconetix beats Anebulo Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.86M	$3.87B	$7.19B	$13.31B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	0.00	13.48	274.25	26.19
Price / Sales	3.53	1,246.24	640.77	107.86
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	0.00	16.18	10.82	6.28
Net Income	-$14.03M	-$22.68M	$3.50B	$381.84M
7 Day Performance	-16.66%	-4.53%	-2.38%	-1.21%
1 Month Performance	-36.08%	-12.48%	-7.36%	-5.59%
1 Year Performance	-99.61%	13.30%	5.44%	0.59%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	1.2371 of 5 stars	$0.66 -0.3%	N/A	-99.6%	$2.89M	$810K	0.00	2
VTGN VistaGen Therapeutics	1.8488 of 5 stars	$0.31 +2.7%	$0.95 +210.5%	-93.6%	$13.54M	$2.50M	N/A	41
TPST Tempest Therapeutics	0.9324 of 5 stars	$0.83 +1.9%	N/A	-92.7%	$13.51M	N/A	N/A	4
INAB IN8bio	3.0971 of 5 stars	$1.36 +4.6%	$4.00 +195.2%	-40.9%	$13.36M	N/A	N/A	18	Gap Down
LSTA Lisata Therapeutics	0.8976 of 5 stars	$1.46 -0.7%	N/A	-51.8%	$13.25M	$100K	N/A	21	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. VTGN, TPST, INAB, LSTA, and ANEB

How does Onconetix compare to VistaGen Therapeutics?

Summary

How does Onconetix compare to Tempest Therapeutics?

Summary

How does Onconetix compare to IN8bio?

Summary

How does Onconetix compare to Lisata Therapeutics?

Summary

How does Onconetix compare to Anebulo Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. VTGN, TPST, INAB, LSTA, and ANEB

How does Onconetix compare to VistaGen Therapeutics?

Do institutionals & insiders hold more shares of VTGN or ONCO?

Which has more risk and volatility, VTGN or ONCO?

Do analysts recommend VTGN or ONCO?

Is VTGN or ONCO more profitable?

Which has stronger valuation and earnings, VTGN or ONCO?

Does the media refer more to VTGN or ONCO?

Summary

How does Onconetix compare to Tempest Therapeutics?

Which has more risk & volatility, TPST or ONCO?

Is TPST or ONCO more profitable?

Does the media refer more to TPST or ONCO?

Do analysts recommend TPST or ONCO?

Do insiders and institutionals have more ownership in TPST or ONCO?

Which has preferable valuation and earnings, TPST or ONCO?

Summary

How does Onconetix compare to IN8bio?

Which has better earnings & valuation, INAB or ONCO?

Do analysts recommend INAB or ONCO?

Does the media refer more to INAB or ONCO?

Is INAB or ONCO more profitable?

Do insiders & institutionals have more ownership in INAB or ONCO?

Which has more risk and volatility, INAB or ONCO?

Summary

How does Onconetix compare to Lisata Therapeutics?

Which has better valuation and earnings, ONCO or LSTA?

Do institutionals & insiders believe in ONCO or LSTA?

Do analysts rate ONCO or LSTA?

Which has more risk & volatility, ONCO or LSTA?

Does the media favor ONCO or LSTA?

Is ONCO or LSTA more profitable?

Summary

How does Onconetix compare to Anebulo Pharmaceuticals?

Do analysts prefer ONCO or ANEB?

Do institutionals & insiders have more ownership in ONCO or ANEB?

Which has higher valuation & earnings, ONCO or ANEB?

Which has more volatility & risk, ONCO or ANEB?

Does the media favor ONCO or ANEB?

Is ONCO or ANEB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools